🇺🇸 RBP-6000 in United States

12 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 23 April 2025 – 23 April 2026
• Total reports: 12

Most-reported reactions

1. Overdose — 2 reports (16.67%)
2. Toxicity To Various Agents — 2 reports (16.67%)
3. Anxiety — 1 report (8.33%)
4. Drug Abuse — 1 report (8.33%)
5. Drug Diversion — 1 report (8.33%)
6. Drug Screen Positive — 1 report (8.33%)
7. Drug Withdrawal Syndrome — 1 report (8.33%)
8. Feeling Abnormal — 1 report (8.33%)
9. Hyperhidrosis — 1 report (8.33%)
10. Injection Site Nodule — 1 report (8.33%)

Source database →

Frequently asked questions

Is RBP-6000 approved in United States?

RBP-6000 does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for RBP-6000 in United States?

Indivior Inc. is the originator. The local marketing authorisation holder may differ — check the official source linked above.